{"pmid":32380316,"pmcid":"PMC7198427","title":"Convalescent plasma in Covid-19: Possible mechanisms of action.","text":["Convalescent plasma in Covid-19: Possible mechanisms of action.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, antibiotics and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of PC are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality.","Autoimmun Rev","Rojas, Manuel","Rodriguez, Yhojan","Monsalve, Diana M","Acosta-Ampudia, Yeny","Camacho, Bernardo","Gallo, Juan Esteban","Rojas-Villarraga, Adriana","Ramirez-Santana, Carolina","Diaz-Coronado, Juan C","Manrique, Ruben","Mantilla, Ruben D","Shoenfeld, Yehuda","Anaya, Juan-Manuel","32380316"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, antibiotics and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of PC are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality."],"journal":"Autoimmun Rev","authors":["Rojas, Manuel","Rodriguez, Yhojan","Monsalve, Diana M","Acosta-Ampudia, Yeny","Camacho, Bernardo","Gallo, Juan Esteban","Rojas-Villarraga, Adriana","Ramirez-Santana, Carolina","Diaz-Coronado, Juan C","Manrique, Ruben","Mantilla, Ruben D","Shoenfeld, Yehuda","Anaya, Juan-Manuel"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32380316","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.autrev.2020.102554","keywords":["ace-2 receptor","covid-19","convalescent plasma","coronavirus","cytokines","intravenous immunoglobulins","neutralizing antibodies","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666597097357443072,"score":9.490897,"similar":[{"pmid":32438330,"title":"Convalescent plasma: A possible treatment protocol for COVID- 19 patients suffering from diabetes or underlying liver diseases.","text":["Convalescent plasma: A possible treatment protocol for COVID- 19 patients suffering from diabetes or underlying liver diseases.","BACKGROUND & AIM: As on date, no specific treatment is available for devastating COVID-19 (SARS-CoV-2) infection. This pandemic viral infection has affected over 200 countries within a very short time and created a calamitous situation across the globe. As per WHO guidelines, the treatment is mainly symptomatic and supportive. This clinical protocol has not proven sufficient to save the lives of COVID-19 patients suffering from diabetes or having underlying liver diseases; hence there is utmost need to tackle this situation by other means such as Convalescent Plasma (CP) therapy. METHODS: A comprehensive literature survey was carriedout using Elsevier, PubMed, Taylor & Francis, Springer, Nature and Google search engines. RESULTS: The patients suffering from diabetes or liver dysfunction or any other underlying diseases are at greatest risk of SARS-CoV-2 infection. From the study, it is proved that plasma collected from the recovered patients of viral infection has considerable potential to treat the viral disease without the occurrence of adverse effects. CONCLUSION: The CP therapy can be a possible life saving alternative to treat critical COVID-19 patients having diabetes or underlying liver dysfunction. Hence, randomised clinical trials are recommended at the earliest to save the lives of infected individuals of COVID-19.","Diabetes Metab Syndr","Pawar, Ashish Yashwantrao","Hiray, Apoorva Prashant","Sonawane, Deepak Devidas","Bhambar, Rajendra Sudhakar","Derle, Deelip Vishram","Ahire, Yogesh Suresh","32438330"],"abstract":["BACKGROUND & AIM: As on date, no specific treatment is available for devastating COVID-19 (SARS-CoV-2) infection. This pandemic viral infection has affected over 200 countries within a very short time and created a calamitous situation across the globe. As per WHO guidelines, the treatment is mainly symptomatic and supportive. This clinical protocol has not proven sufficient to save the lives of COVID-19 patients suffering from diabetes or having underlying liver diseases; hence there is utmost need to tackle this situation by other means such as Convalescent Plasma (CP) therapy. METHODS: A comprehensive literature survey was carriedout using Elsevier, PubMed, Taylor & Francis, Springer, Nature and Google search engines. RESULTS: The patients suffering from diabetes or liver dysfunction or any other underlying diseases are at greatest risk of SARS-CoV-2 infection. From the study, it is proved that plasma collected from the recovered patients of viral infection has considerable potential to treat the viral disease without the occurrence of adverse effects. CONCLUSION: The CP therapy can be a possible life saving alternative to treat critical COVID-19 patients having diabetes or underlying liver dysfunction. Hence, randomised clinical trials are recommended at the earliest to save the lives of infected individuals of COVID-19."],"journal":"Diabetes Metab Syndr","authors":["Pawar, Ashish Yashwantrao","Hiray, Apoorva Prashant","Sonawane, Deepak Devidas","Bhambar, Rajendra Sudhakar","Derle, Deelip Vishram","Ahire, Yogesh Suresh"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32438330","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.dsx.2020.05.023","keywords":["ace2","covid-19","convalescent plasma","diabetes","liver diseases","neutralizing antibodies","sars-cov-2"],"locations":["Elsevier"],"topics":["Treatment"],"weight":1,"_version_":1667521393621729281,"score":249.9734},{"pmid":32253318,"pmcid":"PMC7196837","title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients.","text":["Effectiveness of convalescent plasma therapy in severe COVID-19 patients.","Currently, there are no approved specific antiviral agents for novel coronavirus disease 2019 (COVID-19). In this study, 10 severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL of convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 d after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 d. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 d. Several parameters tended to improve as compared to pretransfusion, including increased lymphocyte counts (0.65 x 10(9)/L vs. 0.76 x 10(9)/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesions within 7 d. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was well tolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.","Proc Natl Acad Sci U S A","Duan, Kai","Liu, Bende","Li, Cesheng","Zhang, Huajun","Yu, Ting","Qu, Jieming","Zhou, Min","Chen, Li","Meng, Shengli","Hu, Yong","Peng, Cheng","Yuan, Mingchao","Huang, Jinyan","Wang, Zejun","Yu, Jianhong","Gao, Xiaoxiao","Wang, Dan","Yu, Xiaoqi","Li, Li","Zhang, Jiayou","Wu, Xiao","Li, Bei","Xu, Yanping","Chen, Wei","Peng, Yan","Hu, Yeqin","Lin, Lianzhen","Liu, Xuefei","Huang, Shihe","Zhou, Zhijun","Zhang, Lianghao","Wang, Yue","Zhang, Zhi","Deng, Kun","Xia, Zhiwu","Gong, Qin","Zhang, Wei","Zheng, Xiaobei","Liu, Ying","Yang, Huichuan","Zhou, Dongbo","Yu, Ding","Hou, Jifeng","Shi, Zhengli","Chen, Saijuan","Chen, Zhu","Zhang, Xinxin","Yang, Xiaoming","32253318"],"abstract":["Currently, there are no approved specific antiviral agents for novel coronavirus disease 2019 (COVID-19). In this study, 10 severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL of convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 d after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 d. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 d. Several parameters tended to improve as compared to pretransfusion, including increased lymphocyte counts (0.65 x 10(9)/L vs. 0.76 x 10(9)/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesions within 7 d. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was well tolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials."],"journal":"Proc Natl Acad Sci U S A","authors":["Duan, Kai","Liu, Bende","Li, Cesheng","Zhang, Huajun","Yu, Ting","Qu, Jieming","Zhou, Min","Chen, Li","Meng, Shengli","Hu, Yong","Peng, Cheng","Yuan, Mingchao","Huang, Jinyan","Wang, Zejun","Yu, Jianhong","Gao, Xiaoxiao","Wang, Dan","Yu, Xiaoqi","Li, Li","Zhang, Jiayou","Wu, Xiao","Li, Bei","Xu, Yanping","Chen, Wei","Peng, Yan","Hu, Yeqin","Lin, Lianzhen","Liu, Xuefei","Huang, Shihe","Zhou, Zhijun","Zhang, Lianghao","Wang, Yue","Zhang, Zhi","Deng, Kun","Xia, Zhiwu","Gong, Qin","Zhang, Wei","Zheng, Xiaobei","Liu, Ying","Yang, Huichuan","Zhou, Dongbo","Yu, Ding","Hou, Jifeng","Shi, Zhengli","Chen, Saijuan","Chen, Zhu","Zhang, Xinxin","Yang, Xiaoming"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32253318","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1073/pnas.2004168117","keywords":["covid-19","convalescent plasma","pilot project","treatment outcome"],"topics":["Treatment"],"weight":1,"_version_":1666138493162618880,"score":237.4456},{"pmid":32320384,"title":"Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19.","text":["Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19.","BACKGROUND: Anti-SARS-CoV-2 virus antibody levels in convalescent plasma (CP), which may be useful in severe Anti-SARS-CoV-2 virus infections, have been rarely reported. RESULTS: A total of eight donors were considered for enrollment; two of them were excluded because of ineligible routine check. Of the six remaining participants, five samples were tested weakly positive by the IgM ELISA. Meanwhile, high titers of IgG were observed in five samples. The patient treated with CP did not require mechanical ventilation 11 days after plasma transfusion, and was then transferred to a general ward. CONCLUSIONS: Our serological findings in convalescent plasma from recovered patients may help facilitate understanding of the SARS-CoV-2 infection and establish CP donor screening protocol in COVID-19 outbreak. METHODS: Anti-SARS-CoV-2 antibodies including IgM and IgG were measured by two enzyme-linked immunosorbent assays (ELISA) in convalescent plasma from six donors who have recovered from coronavirus disease 2019 (COVID-19) in Nanjing, China. CP was also utilized for the treatment of one severe COVID-19 patient.","Aging (Albany NY)","Zhang, Libo","Pang, Rongrong","Xue, Xiang","Bao, Jingjing","Ye, Sheng","Dai, Yudong","Zheng, Yishan","Fu, Qiang","Hu, Zhiliang","Yi, Yongxiang","32320384"],"abstract":["BACKGROUND: Anti-SARS-CoV-2 virus antibody levels in convalescent plasma (CP), which may be useful in severe Anti-SARS-CoV-2 virus infections, have been rarely reported. RESULTS: A total of eight donors were considered for enrollment; two of them were excluded because of ineligible routine check. Of the six remaining participants, five samples were tested weakly positive by the IgM ELISA. Meanwhile, high titers of IgG were observed in five samples. The patient treated with CP did not require mechanical ventilation 11 days after plasma transfusion, and was then transferred to a general ward. CONCLUSIONS: Our serological findings in convalescent plasma from recovered patients may help facilitate understanding of the SARS-CoV-2 infection and establish CP donor screening protocol in COVID-19 outbreak. METHODS: Anti-SARS-CoV-2 antibodies including IgM and IgG were measured by two enzyme-linked immunosorbent assays (ELISA) in convalescent plasma from six donors who have recovered from coronavirus disease 2019 (COVID-19) in Nanjing, China. CP was also utilized for the treatment of one severe COVID-19 patient."],"journal":"Aging (Albany NY)","authors":["Zhang, Libo","Pang, Rongrong","Xue, Xiang","Bao, Jingjing","Ye, Sheng","Dai, Yudong","Zheng, Yishan","Fu, Qiang","Hu, Zhiliang","Yi, Yongxiang"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320384","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.18632/aging.103102","keywords":["covid-19","sars-cov-2 virus","anti-sars-cov-2 antibodies","convalescent plasma","coronavirus disease 2019","plasma donation"],"locations":["Nanjing","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138493620846594,"score":218.96399},{"pmid":32345485,"pmcid":"PMC7194745","title":"Treatment for emerging viruses: Convalescent plasma and COVID-19.","text":["Treatment for emerging viruses: Convalescent plasma and COVID-19.","Use of convalescent plasma transfusions could be of great value in the current pandemic of coronavirus disease (COVID-19), given the lack of specific preventative and therapeutic options. This convalescent plasma therapy is of particular interest when a vaccine or specific therapy is not yet available for emerging viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19. This report summarizes existing literature around convalescent plasma as a therapeutic option for COVID-19. It also includes recommendations for establishing a convalescent plasma program, enhancement considerations for convalescent plasma, and considerations around pathogen reduction treatment of convalescent plasma. Time is of the essence to set up protocols for collection, preparation, and administration of apheresis-collected convalescent plasma in response to the current pandemic. The immediate use of convalescent plasma provides prompt availability of a promising treatment while specific vaccines and treatments are evaluated and brought to scale. Further development of improved convalescent plasma, vaccines and other therapeutics depends on quick generation of additional data on pathogenesis and immune response. Additionally, given the lack of information around the natural history of this disease, PRT should be considered to add a layer of safety to protect recipients of convalescent plasma.","Transfus Apher Sci","Brown, Bethany L","McCullough, Jeffrey","32345485"],"abstract":["Use of convalescent plasma transfusions could be of great value in the current pandemic of coronavirus disease (COVID-19), given the lack of specific preventative and therapeutic options. This convalescent plasma therapy is of particular interest when a vaccine or specific therapy is not yet available for emerging viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19. This report summarizes existing literature around convalescent plasma as a therapeutic option for COVID-19. It also includes recommendations for establishing a convalescent plasma program, enhancement considerations for convalescent plasma, and considerations around pathogen reduction treatment of convalescent plasma. Time is of the essence to set up protocols for collection, preparation, and administration of apheresis-collected convalescent plasma in response to the current pandemic. The immediate use of convalescent plasma provides prompt availability of a promising treatment while specific vaccines and treatments are evaluated and brought to scale. Further development of improved convalescent plasma, vaccines and other therapeutics depends on quick generation of additional data on pathogenesis and immune response. Additionally, given the lack of information around the natural history of this disease, PRT should be considered to add a layer of safety to protect recipients of convalescent plasma."],"journal":"Transfus Apher Sci","authors":["Brown, Bethany L","McCullough, Jeffrey"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32345485","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.transci.2020.102790","keywords":["covid-19","convalescent plasma","prt","pathogen reduction","sars-cov-2"],"topics":["Treatment"],"weight":1,"_version_":1666138494996578304,"score":204.05093},{"pmid":32296259,"pmcid":"PMC7158785","title":"Convalescent plasma: A possible treatment of COVID-19 in India.","text":["Convalescent plasma: A possible treatment of COVID-19 in India.","In India, SARS-CoV-2 virus-induced coronavirus disease 2019 (COVID-19) has already infected close to 5500 people, causing the death of 164. While these numbers are not comparable with values observed for the USA, Italy, or Spain, given the population of India, and the fact that the pandemic is now in an exponential stage of growth, the risks of a contagion that affects a large sector of the Indian population are real. There are no current effective strategies to prevent the spread, other than minimizing contact through social distancing, while no fully effective drugs to prevent or treat COVID-19 exist, although several candidate drugs and repurposed antiviral and immune-modulating pharmacotherapies are being tested or in compassionate use. One postexposure prophylaxis, convalescent (immune) plasma (CP), has shown some success in China and previously in the cure and therapy of other coronaviruses, SARS-1 and Middle East respiratory syndrome. Drawn from current patients who are infected with COVID-19, its CP (human anti-SARS-CoV-2 plasma) might be one way to modulate the infectivity of this virus or its effects postinfection.","Med J Armed Forces India","Teixeira da Silva, Jaime A","32296259"],"abstract":["In India, SARS-CoV-2 virus-induced coronavirus disease 2019 (COVID-19) has already infected close to 5500 people, causing the death of 164. While these numbers are not comparable with values observed for the USA, Italy, or Spain, given the population of India, and the fact that the pandemic is now in an exponential stage of growth, the risks of a contagion that affects a large sector of the Indian population are real. There are no current effective strategies to prevent the spread, other than minimizing contact through social distancing, while no fully effective drugs to prevent or treat COVID-19 exist, although several candidate drugs and repurposed antiviral and immune-modulating pharmacotherapies are being tested or in compassionate use. One postexposure prophylaxis, convalescent (immune) plasma (CP), has shown some success in China and previously in the cure and therapy of other coronaviruses, SARS-1 and Middle East respiratory syndrome. Drawn from current patients who are infected with COVID-19, its CP (human anti-SARS-CoV-2 plasma) might be one way to modulate the infectivity of this virus or its effects postinfection."],"journal":"Med J Armed Forces India","authors":["Teixeira da Silva, Jaime A"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32296259","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.mjafi.2020.04.006","keywords":["antibodies","asia","respiratory disease","sars-cov-2 virus"],"locations":["India","USA","Italy","Spain","India","Indian","China","India"],"countries":["India","Spain","China","United States","Italy"],"countries_codes":["IND|India","ESP|Spain","CHN|China","USA|United States","ITA|Italy"],"topics":["Treatment"],"weight":1,"_version_":1666138493202464768,"score":203.0385}]}